sotorasibramucirumabdocetaxelARPIscancerCommon Sense Oncology initiativeFDANational Comprehensive Cancer Networkhigh-risk hormone-sensitive prostate cancerLMICs+3 more
… rather than to high-cost agents with marginal efficacy such as sotorasib or ramucirumab.Third, it is unacceptable to use inferior contro…